Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Rhea-AI Summary

Savara, a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, will host a conference call and webcast on June 26, 2024, at 8:00am ET to discuss the top line results from its pivotal Phase 3 IMPALA-2 trial. This trial assesses the safety and efficacy of molgramostim, an inhaled GM-CSF, in treating autoimmune pulmonary alveolar proteinosis (aPAP). A press release detailing these results will be issued at 6:30am ET on the same day, prior to the call. Stakeholders can access the live webcast through Savara's website or by phone registration, with a replay available for 90 days.

Positive

• Announcement of pivotal Phase 3 IMPALA-2 trial results, a critical milestone for molgramostim.
• Scheduled investor call indicates transparency and active communication with stakeholders.

Negative

• None.

Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the conference call.

Conference Call

To access the live webcast of the call with slides please click here or visit the "Events & Presentations" section of Savara’s website. To access the call by phone, please use this registration link, and you will be provided with dial-in details. A replay of the webcast will be available approximately 24 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.savarapharma.com.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow^® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625514690/en/

Savara Inc. IR & PR

Anne Erickson (anne.erickson@savarapharma.com)

(512) 851-1366

Source: Savara Inc.

FAQ

When will Savara discuss the top line results from the Phase 3 IMPALA-2 trial?

Savara will discuss the top line results from the Phase 3 IMPALA-2 trial on June 26, 2024, at 8:00am ET.

What is the purpose of Savara's Phase 3 IMPALA-2 trial?

The Phase 3 IMPALA-2 trial evaluates the efficacy and safety of molgramostim, an inhaled GM-CSF, in treating autoimmune pulmonary alveolar proteinosis (aPAP).

How can stakeholders access Savara's conference call on June 26, 2024?

Stakeholders can access the conference call via a live webcast on Savara's website or by phone registration. A replay will be available for 90 days.

What is molgramostim?

Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) being assessed for treating autoimmune pulmonary alveolar proteinosis (aPAP).

When will the press release of the Phase 3 IMPALA-2 trial results be issued?

The press release detailing the Phase 3 IMPALA-2 trial results will be issued on June 26, 2024, at 6:30am ET.